- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06630234
Un protocollo principale per valutare il DCC-3009 nel tumore stromale gastrointestinale (GIST)
Un protocollo principale per lo studio multi-coorte, in aperto, di fase 1/2 del DCC-3009 in partecipanti con tumore stromale gastrointestinale (GIST)
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 3 parts: Part 1 (Dose Escalation), Part 2 (Dose Expansion), and Part 3 (Food Effect [FE] and Drug-Drug Interaction [DDI]). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Clinical Team
- Numero di telefono: 888-724-3274
- Email: clinicaltrials@deciphera.com
Luoghi di studio
-
-
Arizona
-
Scottsdate, Arizona, Stati Uniti, 85258
- Reclutamento
- HonorHealth
-
Contatto:
- Program Management
- Email: hriprograms@honorhealth.com
-
-
California
-
La Jolla, California, Stati Uniti, 92093
- Reclutamento
- UC San Diego Moores Cancer Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- University of Colorado Anschutz Medical Campus
-
Contatto:
- Steven Sares
- Numero di telefono: 303-724-9889
- Email: steven.sares@cuanschutz.edu
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Reclutamento
- Mayo Clinic Florida
-
Contatto:
- Caroline Teeter
- Numero di telefono: 904-953-5141
- Email: teeter.caroline@mayo.edu
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami - Sylvester Comprehensive Cancer Center
-
Contatto:
- Leah Anton, ARNP
- Numero di telefono: 305-243-2529
- Email: lxa712@med.miami.edu
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana Farber Cancer Institute
-
Contatto:
- Research Nurse
- Numero di telefono: 617-632-5204
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49546
- Reclutamento
- START Midwest
-
Contatto:
- Hope Team
- Email: hopeteam@startresearch.com
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic Rochester
-
Contatto:
- Jordan Meyers
- Numero di telefono: 507-284-2030
- Email: Meyers.jordan@mayo.edu
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
Contatto:
- Ping Chi, MD
- Numero di telefono: 646-888-4166
- Email: chip@mskcc.org
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University-Ingram Cancer Center
-
Contatto:
- Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)
- Numero di telefono: 800-811-8480
- Email: CTIP@VUMC.ORG
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
Module A:
- Have at least 1 measurable lesion as defined by mRECIST, v1.1
- Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
- Adequate organ function, bone marrow function, and electrolytes
- All participants agree to comply with the contraception requirements
- Have a life expectancy of more than 3 months
Module A Part 1 (Escalation) and Part 3 (FE and DDI):
-Any participant with histologically or cytologically confirmed advanced/unresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced/metastatic setting
Module A Part 2 (Expansion):
-Any participant with histologically or cytologically confirmed advanced or metastatic GIST with documented KIT or PDGFRA mutation
Module A Part 3 (FE and DDI):
-Able to consume a high-fat meal
Key Exclusion Criteria:
- Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug
- Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer
- Has known active central nervous system (CNS) metastases or an active primary CNS cancer
- History or presence of clinically relevant cardiovascular abnormalities
- Major surgery within 28 days of the first dose of study drug
- Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug
- Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug
- Known allergy or hypersensitivity to any component of the study drug
- Malabsorption syndrome or other illness that could affect oral absorption
- Any other clinically significant comorbidities
Module A Part 3 (FE and DDI):
- Allergy or hypersensitivity to rabeprazole or any of its excipients
- Unable or unwilling to adhere to overnight fasting of 10 hours
Other protocol-specified inclusion and exclusion criteria apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: DCC-3009 Module A
Participants will receive DCC-3009 in 28 day cycles in Module A Part 1 dose escalation, Part 2 dose expansion, and Part 3 FE and DDI. Participants in Part 3 will also receive rabeprazole. |
Administered orally Administered orally (Part 3 only) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants with Dose-Limiting Toxicities (DLT) (Part 1 Escalation)
Lasso di tempo: Cycle 1 (28 Days)
|
DLTs assessed for each dose level. |
Cycle 1 (28 Days)
|
|
Number of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)
Lasso di tempo: Cycle 1 (28 Days)
|
Cycle 1 (28 Days)
|
|
|
Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)
Lasso di tempo: Cycle 1 (28 Days)
|
Cycle 1 (28 Days)
|
|
|
Objective Response Rate (ORR) (Part 2 Expansion)
Lasso di tempo: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST), v1.1. |
Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
|
Pharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate (ORR) (Part 1 Escalation and Part 3 FE and DDI)
Lasso di tempo: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on mRECIST, v1.1. |
Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
|
|
Disease Control Rate (DCR)
Lasso di tempo: Weeks 16, 24, 32
|
DCR is the proportion of participants who achieve CR, PR, or stable disease at the specified time point per mRECIST, v1.1. |
Weeks 16, 24, 32
|
|
Duration of Response (DOR)
Lasso di tempo: First Recorded CR or PR until PD or Death (Estimated up to 24 months)
|
DOR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the disease progression is objectively documented or death, whichever occurs first. |
First Recorded CR or PR until PD or Death (Estimated up to 24 months)
|
|
Time to Response (TTR)
Lasso di tempo: Baseline to First Recorded CR or PR (Estimated up to 24 months)
|
TTR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per mRECIST, v1.1. |
Baseline to First Recorded CR or PR (Estimated up to 24 months)
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Initiation of Treatment to PD or Death (Estimated up to 24 months)
|
PFS is the time from initiation of treatment until documented disease progression per mRECIST, v1.1, or death, whichever occurs first. |
Initiation of Treatment to PD or Death (Estimated up to 24 months)
|
|
Overall Survival (OS)
Lasso di tempo: Initiation of Treatment to Death from Any Cause (Estimated up to 24 months)
|
OS is the time from initiation of treatment to the date of death from any cause. |
Initiation of Treatment to Death from Any Cause (Estimated up to 24 months)
|
|
PK: Tmax (Part 1 Escalation and Part 2 Expansion)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Cmax (Part 1 Escalation and Part 2 Expansion)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: Ctrough (Part 1 Escalation and Part 2 Expansion)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
PK: AUC (Part 1 Escalation and Part 2 Expansion)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
Number of Participants with TEAEs or SAEs (Part 2 Expansion and Part 3 FE and DDI)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
|
|
Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 2 Expansion and Part 3 FE and DDI)
Lasso di tempo: Estimated up to 24 months
|
Estimated up to 24 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Clinical Team, Deciphera Pharmaceuticals, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie, Connettivo e Tessuto Molle
- Neoplasie, tessuto connettivo
- Tumori stromali gastrointestinali
- 2-piridinilmetilsolfinilbenzimidazoli
- Solfossidi
- Composti di zolfo
- Prodotti chimici organici
- Piridine
- Composti eterociclici, 1-anello
- Composti eterociclici
- Benzimidazoli
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Rabeprazolo
Altri numeri di identificazione dello studio
- DCC-3009-01-001
- 2026-525379-20-00 (Ctis)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .